ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
India’s Intas Pharmaceuticals will pay $740 million to buy the U.K. and Ireland business of Actavis Generics from Teva Pharmaceutical Industries. The European Union said Teva had to divest the business to win approval for its 2015 acquisition of Actavis Generics from Allergan. Intas says the new business will double its sales in Europe to $500 million annually and make it a top-20 player in generics.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter